Abstract： Objective To investigate the effect and safety of atovastatin calcium on dyslipidemia and hypersensitive C-reactive protein in hypertension patients. Methods One hundred and twenty-eight hypertensive patients with dyslipidedmia were divided into two groups: control group and treatment group. All patients were in low-fat and low-cholesterol diet and received antihypertensive treatment as usual. Patients in treatment group took atovastatin (20 mg/day) for 12 weeks. Systolic blood pressure (SBP), diastolic blood pressure(DBP), serum total glycerin (TG), total cholesterol ( TC ), low-dense-lipoprotein cholesterol ( LDL-C ), high-dense-lipoprotein cholesterol (HDL-C), very low-dense-lipoprotein cholesterol (VLDL-C), hypersensitive C-reactive protein (hs-CRP), creatinin (Cr), glutamate pyruvate transaminase (ALT) and creatine kinase (CK) were measured before and after the treatment. Results In patients with atovastatin treatment, TG was reduced 16%[(1.6 ±1.2)mmoL/L vs (2.0 ±0.9) mmol/L, P ＜ 0.05], TC was reduced 24% [(4 ± 1 ) mmol/L vs (6 ± 1 ) mmoL/L, P ＜ 0.01], LDL-C was reduced 34% [(3 ± 1 ) mmol/L vs (4 ± 1 ) mmol/L, P ＜ 0.01] and hs-CRP was significantly reduced [(2.3 ± 1.5 )mg/L vs (5.3 ± 2.9)mg/L, P ＜ 0.01]. CK increased lightly in two patients with atovastatin treatment and were in normal range in one month although the patients received atovastatin ( 10 mg/day) treatment. Compared to control group, TC, LDL-C, VLDL-C and hs-CRP were significantly reduced in treatment group. There was no significant difference in HDL-C, SBP, DBP, Cr and ALT. Conclusion Atovastatin can decrease hypersensitive C-reactive protein in hypertension patients with dyslipidemia.